Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06801821

Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis

Primary objective:

The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis, vitiligo, and alopecia areata.

* Compare the social distance and stereotyping by the general population toward individuals with facial involvement by: psoriasis, atopic dermatitis, vitiligo, and alopecia areata. * Evaluate demographic factors that describe a greater tendency toward stigmatization.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Basic demographic characteristics (Gender, Age, Employment status, Education level) will be recorded for each patient.

Participants will be asked to observe images depicting faces of individuals with atopic dermatitis, alopecia areata, vitiligo, and psoriasis (generated through artificial intelligence systems). They will be asked to select the individual from those shown that generates the most compassion/pity, disgust, blame/disapproval/disdain, and curiosity for them, analyzing the same emotional responses investigated in a study on stigma toward psoriasis patients.

In addition, each participant will be given a 14-question questionnaire on stigma (analyzing social distance and stereotyping) toward one of the four diseases under investigation (psoriasis, atopic dermatitis, vitiligo, or alopecia areata), selected randomly. For each question, responses will be expressed from 1 to 5, on a Likert scale, with lower scores indicating greater stigma. (Total score between 14 and 70)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • -Patients aged>18 years, both sexes;
  • Signature of written informed consent;

Exclusion criteria

  • Patients diagnosed with psoriasis, atopic dermatitis, vitiligo or alopecia areata.
  • Patients with first-degree relatives with psoriasis, atopic dermatitis, vitiligo or alopecia areata
  • Those who for professional or personal reasons have direct knowledge of the diseases in question.

Treatment and study plan

Primary outcomes

  1. primary endopoint

    Time frame: 12 months

    Compare the percentage of patients associating the 4 different emotional reactions analyzed (compassion/pity, disgust, blame/disapproval/dislike, and curiosity) with each dermatologic condition under study.

Study contacts

Contact information is provided by the study sponsor or research team.

Caldarola

CONTACT

[email protected]

+390630155284

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Acronym: STIGMADERM

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 30, 2025
Registry last updated
Aug 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.